[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Biobizkaia Health Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":213},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,38,61,88,129,161,184],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100637608","adapted-physical-activity-apa-following-hospitalization-in-frail-older-adults-100637608",false,"NCT07617714","Adapted Physical Activity (APA) Following Hospitalization in Frail Older Adults","Inclusion Criteria:\n\n* The study is open to individuals aged 65 and older.\n* Current diagnosis or recent history of cancer.\n* Patients currently undergoing treatment (chemotherapy, immunotherapy, targeted therapy) or in follow-up after recent treatment (≤12 months since completion).\n* Functional capacity compatible with participation in an adapted physical activity program, as determined by clinical assessment.\n* Recent hospitalization: Patients must have been discharged following a hospital stay.\n* Frailty: Presence of a significant level of frailty at hospital discharge.\n\nExclusion Criteria:\n\n* Short Physical Performance Battery\\> 10: Patients considered \"robust\" are excluded to maximize the relevance of the intervention.\n* Acute unstable medical condition or contraindication to exercise: Any unstabilized acute condition that makes physical activity dangerous (e.g., acute cardiac complication, ongoing severe infection). Recent major medical events (myocardial infarction, major surgery, bone fracture, or major amputation in the past few weeks) will also be excluded.\n* Severe chronic conditions incompatible with exercise: Severe progressive diseases that prevent safe exercise, such as severe neuromuscular diseases or advanced organ failure (e.g., end-stage renal failure).\n* Short-term life-threatening prognosis: Patients in the terminal phase or with a very limited life expectancy (less than 6 months).\n* Total functional dependence or severe motor impairment: Patients who are completely dependent for basic activities (very low Barthel Index, e.g., \\\u003C20\u002F100) or who are unable to move even minimally (e.g., unable to walk a few steps or stand, even with assistance).\n* Severe cognitive impairment: Severe cognitive impairment (e.g., advanced dementia without the ability to follow simple instructions) that prevents active participation in the program.\n* Severe sensory or communication disorders: Significant sensory impairments-such as profound uncompensated blindness or deafness-or any communication barrier (severe aphasia, language barrier) that prevents participation in the program, unless a caregiver (family member or professional) can be present to ensure safety during the exercises.\n* Institutionalization of the patient: Individuals who do not live in their usual residence are excluded. The study focuses on older adults returning home, as the institutional setting involves different care.\n* Lack of valid informed consent: Any patient who refuses to participate or who cannot provide valid consent (due to lack of legal capacity or understanding) will be excluded.\n* Participation in another concurrent program or trial: Simultaneous participation in another physical exercise program or trial.","ALL","65 Years",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"NA","To evaluate the effectiveness of an Adapted Physical Activity (APA) program in improving functional capacity and reducing frailty in older adults following hospital discharge.\n\nThe aim is to determine whether a structured program of personalized exercises improves mobility, strength, and quality of life compared to standard care.",[25],"Oncologic Disease","NOT_YET_RECRUITING","2026-06-01",{"date":29,"type":30},"2026-06-02","ACTUAL",{"date":32,"type":19},"2026-06",{"date":34,"type":19},"2027-12-31",{"name":36,"class":37},"Biobizkaia Health Research Institute","OTHER_GOV",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":45,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":20,"phases":47,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},"100623991","phase-4-efficacy-of-faricimab-in-patients-with-subretinal-hyper-reflective-material-100623991","NCT07403825","Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material","Efficacy of Faricimab in Patients With Subretinal Hyperreflective Material Associated With Type 2 or Mixed Neovascular Membranes Assessed by Multimodal Imaging","Inclusion Criteria:\n\n* People aged 50 and over.\n* Diagnosed with bilateral or unilateral AMD.\n* Eyes with SHRM and type 2 or mixed (type 1 and 2) neovascular membrane.\n* Näive eyes treated with Faricimab following SmPC (summary of product characteristic).\n* They agree to participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Eyes with type 1, aneurysmal type 1 and type 3 MNV.\n* Eyes with type 2 MNV and other macular diseases (myopia, posterior uveitis, systemic diseases, such as pseudoxanthoma elasticum).\n* Eyes with ocular media opacity.\n* Patients with other retinal diseases, such as central serous chorioretinopathy, diabetic retinopathy, retinal vascular occlusion, uveitis, myopic maculopathy or any other retinal disease that could compromise the best-corrected visual acuity and interfere with retinal parameters.\n* Any neurological condition (including cognitive impairment, stroke, dementia, Parkinson, anxiety or schizophrenia) that, in the opinion of the investigator, would pose a risk to patient's safety or interfere with the assessment, procedures, or completion of the study.\n* People who are participating or will participate in any type of clinical trial.\n* Pregnant women.\n* Breastfeeding women.\n* Women\\* of childbearing potential who are unable or unwilling to use highly effective methods of contraception (bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices) from the start to the end of the study.\n\n  * Woman of childbearing potential: considered as such if she is postmenarcheal, has not reached a postmenopausal state (≥12 continuous months of amenorrhea with no identified cause other than menopause), or has not undergone surgical sterilization (removal of ovaries and\u002For uterus).","50 Years",{"count":18,"type":19},[48],"PHASE4","Whose aim is to:\n\nDetermine the percentage of patients with resolution of subretinal hyperreflective material (SHRM) at week 16.\n\nThis study is intended to be performed in the ophthalmology departments or ophthalmology clinics of the participating sites, located in Spain.\n\nMacular degeneration is an eye disease characterised by progressive damage to the macula leading to a loss of central vision. There are two types of macular degeneration, dry and wet or exudative. The prevalence of the latter in Spain is 1.9% in people aged 65 and over. Among the subtypes of macular neovascularisation (MNV), type 2 is rare (9%), with the majority being mixed type 1 and 2 cases (13.5%). SHRM is present in about 77% of eyes with neovascular age-related macular degeneration (AMD).\n\nDifferent anti-VEGF (vascular endothelial growth factor) drugs have been used for the treatment of type 2 and mixed 1 and 2 types of MNV. Following treatment, a reduction in SHRM has been observed, although results between studies vary between 34% and 56%. Improvements in best-corrected visual acuity are also achieved in eyes with type 2 MNV with anti-VEGF therapy.",[51],"Macular Degeneration, Age Related","RECRUITING","2026-05-25",{"date":55,"type":30},"2026-05-28",{"date":53,"type":30},{"date":58,"type":19},"2028-10",{"name":36,"class":37},10,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":15,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":20,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100627411","phase-3-clinical-trial-to-evaluate-the-efficacy-and-safety-of-platelet-rich-plasma-infiltration-in-chronic-omalgia-100627411","NCT07448285","Clinical Trial to Evaluate the Efficacy and Safety of Platelet-rich Plasma Infiltration in Chronic Omalgia","Randomized Clinical Trial to Evaluate the Efficacy and Safety of Platelet-Rich Plasma (PRP) Injection Combined With Physical Exercise in Chronic Omalgia","Inclusion Criteria:\n\n* Patients between 35 and 75 years of age, both inclusive.\n* Presence of pain in the affected shoulder for 3 or more months.\n* Body Mass Index (BMI) values between 20 and 27 kg\u002Fm2, including both values.\n* Confirmed diagnosis of chronic shoulder pain associated with rotator cuff tendinopathy, following an unfavorable response to standard treatment with analgesics and nonsteroidal anti-inflammatory drugs for 4-6 weeks.\n* Patients who agree to participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Confirmed diagnosis of complete rotator cuff tear.\n* Patients with systemic autoimmune rheumatic disease (connective tissue diseases and systemic necrotizing vasculitis).\n* Patients with diabetes mellitus.\n* Patients with hematological disorders (thrombopathy, thrombocytopenia, anemia with Hb\\\u003C9 g\u002Fdl).\n* Patients undergoing immunosuppressive treatment at the time of inclusion.\n* Patients undergoing treatment with intramuscular corticosteroids in the 3 months prior to the first administration of the trial treatment.\n* Patients undergoing treatment with nonsteroidal anti-inflammatory drugs (more than 10 consecutive days at usual doses), opioids, or oral corticosteroids during the 15 days prior to treatment in the study.\n* Patients with severe heart disease.\n* Patients with active cancer or cancer diagnosed in the last 5 years.\n* Patients who are taking a drug in clinical trials or have participated in any clinical trial (with an authorized or unauthorized product) in the 30 days prior to randomization.\n* Patients with any physical, social, or psychological condition that, in the opinion of the investigators, may affect the patient's participation in the trial or the validity of the data obtained from their participation in it.\n* Pregnant women.\n* Breastfeeding women.\n* Women of childbearing age\\* who are unable or unwilling to use contraceptive methods with a failure rate of \\\u003C1% per year (bilateral tubal ligation, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices) during the four-week treatment period.","35 Years","75 Years",{"count":71,"type":19},86,[73],"PHASE3","The experimental group will receive intralesional injections of platelet-rich plasma, evaluating its ability to relieve pain and provide sustained improvement through biological modulation of the joint and tendon environment. In contrast, the control group will be treated with a combination of betamethasone and ropivacaine, representing the current standard of care for short-term inflammatory pain management. The comparison between these two options will determine whether platelet-rich plasma offers advantages in terms of clinical efficacy and duration of benefits. The results obtained could contribute significantly to the development of more effective protocols and more precise management guidelines for patients with chronic omalgia, thus addressing existing controversies and improving clinical practice.",[76],"Chronic Pain",[78],"omalgia","2026-03-02",{"date":81,"type":30},"2026-03-04",{"date":83,"type":30},"2026-02-24",{"date":85,"type":19},"2029-04",{"name":36,"class":37},2,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":15,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":100,"studyType":101,"phases":4,"briefSummary":102,"conditions":103,"keywords":107,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},"100611396","reduction-of-the-incidence-of-nav-in-neonatal-units-inbernav-neo-100611396","NCT07240038","Reduction of the Incidence of NAV in Neonatal Units (INBERNAV-Neo)","Evaluation of an Evidence Based, Bundled Intervention to Reduce Incidence of Ventilator-associated Pneumonia in Neonatal Units (INBERNAV-Neo)","INBERNAV-Neo","Inclusion Criteria:\n\n* Patients admitted to participating NICUs who are in IMV for at least 48 hours, regardless of birth weight, gestational age or medical condition.\n\nExclusion Criteria:\n\n* Patients who remain in IMV less than 48 hours.\n* Decision of the healthcare professional in charge of the patient's treatment to exclude their participation at any moment due to the considerations of necessity.","0 Days","6 Months",{"count":99,"type":19},1500,"365 Days","OBSERVATIONAL","The aim of this project is to achieve useful, universal and standardized definitions for the diagnosis and prevention of ventilator-associated neumonia in patients in the Neonatal Intensive Care Unit (NICU). To this end, a set of recommendations and best practice protocols have been developed in which the healthcare team of the participating units will be trained. These protocols will include evidence-based recommendations for daily practice (oral care, suctioning practices, patient positioning...) and guidelines for the diagnosis, with the goal of improving and standardizing the care that is currently carried out in each unit.\n\nTo evaluate the extent to which this intervention helps to reduce the frequency of ventilator-associated pneumonia and minimize its impact, a surveillance registry of the patient on invasive mechanical ventilation will be carried out. This registry consists of the collection of general data (sex, type of delivery, gestational age...), the drugs used during the registry (use or not of antibiotics) and the duration of the period during which the patient is under surveillance. If the patient develops pneumonia during the duration of intubation, the clinical and radiological (and in some cases microbiological) data necessary for its diagnosis and the treatment used will be collected.\n\nThe study is composed of several phases, but if we exclude the phases of formation and structure of the teams, literature review, resource preparation and data processing, the study is composed of 3 clearly differentiated phases in which patients are included. In the first phase, the coordinating team will only give the researchers of each hospital access to the forms and a brief explanation of how to fill them in, but instructing them to follow the usual diagnostic criteria. Once an established period of time has finished, the whole team belonging to the NICUs included in the project will be trained. Finally, after the training period, the teams will incorporate the preventive measures and diagnostic criteria seen in the training to their usual practice. To track behavioral changes from one phase to the next, the researchers will fill out forms to monitor the implementation of measures. Once this last phase has been completed, the results obtained will be analysed and the changes in prevention and diagnosis will be evaluated.",[104,105,106],"Pneumonia Ventilator Associated","Pneumonia Neonatal","Healthcare-associated Infections",[108,109,110,111,112,113,114,115,116,117,118,119],"neonate","ventilator-associated pneumonia","quasi-experimental","multicenter","prevention","epidemiologic surveillance","clinical diagnosis","microbiological diagnostics","NICU","intervention","good clinical practice","patient safety","2025-11-19",{"date":122,"type":30},"2025-11-20",{"date":124,"type":30},"2024-04-26",{"date":126,"type":19},"2026-06-30",{"name":36,"class":37},39,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":137,"sex":15,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":20,"phases":142,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},"100586962","the-sunrise-project-is-dedicated-to-enhancing-primary-cancer-prevention-among-adolescents-in-europe-by-leveraging-innovative-digital-tools-and-methodologies-smartcoach-developed-by-swiss-research-institute-for-public-health-and-addiction-isgf-is-a-mobile-phone-based-life-skills-training-program-100586962","NCT06922201","The SUNRISE Project is Dedicated to Enhancing Primary Cancer Prevention Among Adolescents in Europe by Leveraging Innovative Digital Tools and Methodologies. SmartCoach, Developed by Swiss Research Institute for Public Health and Addiction (ISGF), is a Mobile Phone-based Life-skills Training Program","SUstaiNable inteRventions and Healthy behavIours for adoleScent Primary prEvention of Cancer With Digital Tools. Study 1: SmartCoach","SUNRISE_1","Inclusion Criteria:\n\n* Minimum Age: Students must be at least 14 years old at the time of enrolment.\n* Mobile Device and Internet Access: Students must have access to a smartphone and the Internet.\n* Informed Consent: Students must provide their signed informed consent to participate in the study.\n* Parental Consent: Students must obtain and submit signed informed consent from a parent or legal guardian.\n\nExclusion Criteria:\n\n* Age Restrictions: Students who are younger than 14 years or older than the established age range for participation.\n* Consent Issues: Students who have not signed the informed consent form or do not have signed informed consent from their parents or legal guardians.\n* Follow-up Limitations: Students who are unable to commit to the follow-up period of at least 18 months or are unlikely to complete the study.",true,"14 Years","18 Years",{"count":141,"type":19},3500,[22],"SUNRISE aims to create a comprehensive, engaging, and sustainable digital health promotion program that not only addresses immediate health behaviours but also instills lifelong healthy habits among adolescents. By integrating cutting-edge digital tools with traditional educational settings, SUNRISE seeks to bridge the gap between knowledge and practice, making cancer prevention a tangible and achievable goal for young people. This study represents a significant step towards reducing the future burden of cancer through early and innovative preventive measures.\n\nThe SUNRISE project aims to test its intervention on students across eight European countries, including Greece, Switzerland, Slovenia, Spain, Cyprus, Italy, Belgium, and Romania. This study focuses on integrating digitally enhanced programs into the school environment, targeting students aged 10 to 19 years. The program emphasizes inclusivity, ensuring participation from both urban and rural regions and socially disadvantaged groups such as ethnic minorities and migrants. By addressing diverse socio-economic, cultural, and environmental contexts, SUNRISE aspires to create a universally applicable and impactful intervention.\n\nSpecifically, this study is focus on the SmartCoach program, developed by the Swiss Research Institute for Public Health and Addiction (ISGF). It is a mobile phone-based life-skills training program designed to prevent substance use among adolescents. It will integrate digital tools and leveraging social media creating a more engaging, effective and sustainable intervention for adolescent health behaviour change.\n\nThe SmartCoach solution will be significantly more effective than an assessment-only approach in preventing the initiation and escalation of problematic alcohol and tobacco use. This efficacy will be demonstrated through a two-arm cluster-randomized controlled trial, with participants assessed at baseline, 6 months, and 18 months. The study will measure key outcomes related to substance use frequencies, intensities, and associated behavioral changes, showing that the individually tailored 4 month intervention program leads to greater reductions in these behaviors compared to the control group over the 18-month follow-up period.",[145],"Cancer",[147,148,149,150,151],"SUNRISE","SmartCoach","Life-skills training","substance use prevention","adolescents","2025-04-09",{"date":154,"type":30},"2025-04-10",{"date":156,"type":19},"2025-09",{"date":158,"type":19},"2028-04",{"name":36,"class":37},8,{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":137,"sex":15,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":173,"studyType":101,"phases":4,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":182,"leadSponsor":183,"locationsCount":160},"100587704","sunrise-aims-to-create-a-comprehensive-engaging-and-sustainable-digital-health-promotion-program-that-not-only-addresses-immediate-health-behaviours-but-also-instils-lifelong-healthy-habits-among-adolescents-it-is-a-unique-digitally-enhanced-program-combining-different-digital-solutions-with-new-100587704","NCT06931847","SUNRISE Aims to Create a Comprehensive, Engaging, and Sustainable Digital Health Promotion Program That Not Only Addresses Immediate Health Behaviours But Also Instils Lifelong Healthy Habits Among Adolescents. It is a Unique, Digitally Enhanced Program Combining Different Digital Solutions With New","SUstaiNable inteRventions and Healthy behavIours for adoleScent Primary prEvention of Cancer With Digital Tools. Study 2: Multiple Behaviour Intervention Platform","SUNRISE_2","Inclusion Criteria:\n\n* Minimum Age: Students must be at least 10 years old at the time of enrolment.\n* Devices and Internet Access: Students must have access to an electronic device with Internet connectivity.\n* Informed Consent: Students must provide their signed informed consent to participate in the study.\n* Parental Consent: Students, when necessary, must obtain and submit signed informed consent from a parent or legal guardian.\n\nExclusion Criteria:\n\n* Age Restrictions: Students who are younger than 10 years or older than the established age range for participation.\n* Consent Issues: Students who have not signed the informed consent form or do not have signed informed consent from their parents or legal guardians.\n* Follow-up Limitations: Students who are unable to commit to the follow-up period of at least 18 months or are unlikely to complete the study.","10 Years","19 Years",{"count":172,"type":19},4000,"18 Months","SUNRISE aims to create a comprehensive, engaging, and sustainable digital health promotion program that not only addresses immediate health behaviours but also instills lifelong healthy habits among adolescents. By integrating cutting-edge digital tools with traditional educational settings, SUNRISE seeks to bridge the gap between knowledge and practice, making cancer prevention a tangible and achievable goal for young people. This study represents a significant step towards reducing the future burden of cancer through early and innovative preventive measures.\n\nThe SUNRISE project aims to test its interventions on students across eight European countries, including Greece, Switzerland, Slovenia, Spain, Cyprus, Italy, Belgium, and Romania. This study focuses on integrating a unique, digitally enhanced program combining different digital solutions with new methods to change adolescent health behaviour through social media campaigns, social bot platforms, educational games, and health-related advertising content into the school environment, targeting students aged 10 to 19 years.\n\nThe program emphasizes inclusivity, ensuring participation from both urban and rural regions and socially disadvantaged groups such as ethnic minorities and migrants. By addressing diverse socio-economic, cultural, and environmental contexts, SUNRISE aspires to create a universally applicable and impactful intervention.",[145],[147,151,112,177,178],"healthy behaviour","Digital solutions",{"date":180,"type":30},"2025-04-17",{"date":156,"type":19},{"date":158,"type":19},{"name":36,"class":37},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":137,"sex":15,"minAge":191,"maxAge":192,"enrollmentInfo":193,"targetDuration":195,"studyType":101,"phases":4,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":212},"100552498","understanding-lung-cancer-related-risk-factors-and-their-impact-100552498","NCT06473870","Understanding Lung Cancer Related Risk Factors and Their Impact","LUCIA","Inclusion Criteria (for the 3 phases):\n\n* Subjects aged between 40 and 80 years\n* Both genders, of which at least 37% must be women to ensure representativeness\n* Willingness and ability to comply with scheduled visits, laboratory tests, and other trial procedures\n* Written informed consent obtained prior to performing any protocol-related procedures.\n\nInclusion criteria for Phase 2: Precision Screening:\n\n* High risk of developing Lung Cancer volunteers will be selected by Lung Cancer risk factors modelling.\n\nInclusion criteria for Phase 3: Diagnosis:\n\n\\- Patients diagnosed with indeterminate pulmonary nodules or Lung Cancer from the screening phases.\n\nExclusion Criteria:\n\n* Subjects under 40 years of age\n* Unable to be followed-up for at least 2-years or complete the study\n* Subjects that do not sign the informed consent\n* Current or prior history of lung cancer\n* History of neoplasia in the previous 5 years except non-melanoma skin cancer\n* Moderate-severe comorbidities that prevent completion of a diagnostic study in the event of findings suggestive of lung neoplasia (by means of the investigator's clinical judgment) or surgical intervention (\\\u003C 6 months) if not previously confirmed by cytohistology.\n* Vulnerable subjects: severe psychiatric comorbidity, adults under guardianship or deprived of liberty\n* Pregnant women","40 Years","80 Years",{"count":194,"type":19},6160,"2 Years","LUCIA aims to develop prediction models for the early diagnosis of lung cancer based on the identification of risk factors and deeper cellular knowledge, by recording real-world data; with risk assessment tools, non-invasive devices and omics analysis. These models will enable new clinical pathways and diagnostic workflow to be implemented to ensure early diagnosis and confirmation, including classification of lung cancer subtype.",[198],"Lung Cancer Screening",[200,201,202,203],"Lung Cancer","Lung cancer screening","LDCT","Risk factors","2024-06-19",{"date":206,"type":30},"2024-06-25",{"date":208,"type":19},"2024-07",{"date":210,"type":19},"2027-12",{"name":36,"class":37},5,""]